A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants

Sponsor
Eli Lilly and Company
Study ID
NCT03841630
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
21 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • LY3437943 — DRUG
    Administered subcutaneously (SC)
  • Placebo — DRUG
    Administered SC

Study Details

This study is being conducted to determine the side effects related to LY3437943 given as a single injection under the skin to healthy participants. Blood tests will be performed to check how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of LY3437943 or placebo. The study will last up to approximately 71 days for each participant, including screening.

Key Dates

Start date
Mar 13, 2019
Status verified
Aug 2019
Primary completion
Jul 25, 2019
Completion
Jul 25, 2019

Study Design

Enrollment
45 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY3437943
    Escalating doses of LY3437943 administered as an injection under the skin in healthy participants
  • Placebo Comparator: Placebo
    Matching placebo administered as an injection under the skin in healthy participants

Primary Outcome Measure

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through final follow-up at approximately Day 43 ]

Related Studies